Alumis Inc. (ALMS) SEC Filings & Earnings Calls

Impairment loss on lonigutamab program.

“$41.8 million impairment loss related to acquired IPR&D intangible asset.” · word for word

Lonigutamab program impairment and strategic uncertainty

“In May 2026, the Company completed its strategic review of the lonigutamab program and decided to pursue strategic alternatives for the program. This decision represented a triggering event under ASC 350 and required the Company to perform an interim impairment assessment of the acquired IPR&D intangible asset. Based on the results of the impairment assessme” · word for word

Ongoing securities class action lawsuit

“On November 15, 2023, a purported federal securities class action lawsuit was commenced... The complaint alleges that the defendants violated the Exchange Act and Securities Act by misleading investors about the Phase 2b trial of izokibep in hidradenitis suppurativa.” · word for word

Need for substantial additional capital

“We will need to raise significant additional capital to fund ongoing research and development activities and maintain future operations.” · word for word

Clinical trial and regulatory risk for envu

“We plan to submit an NDA for envu in PsO to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026.” · word for word

Tariff exposure on pharmaceutical imports

“the President issued a proclamation imposing up to a 100% tariff on certain patented pharmaceuticals and associated pharmaceutical ingredients, including a 15% tariff on imports from South Korea and EU member states. These tariffs will become effective September 29, 2026” · word for word

Clinical development risk

“The Company will need to raise significant additional capital to fund ongoing research and development activities and maintain future operations.” · word for word

Revenue concentration risk

“All of the Company's revenues are currently earned under its license and collaboration agreement with Kaken. As a result, the Company is subject to customer concentration risk.” · word for word

Geopolitical and trade risk

“The United States and other countries have imposed and may continue to impose new trade restrictions and export regulations, have levied tariffs and taxes on certain goods, including tariffs targeting pharmaceutical products and related inputs.” · word for word

IPR&D impairment risk

“Subsequent to March 31, 2026, the Company completed its strategic review of the lonigutamab program and decided to explore strategic alternatives for the program. The outcome of this evaluation could represent an event or change in circumstances that may require the Company to perform an interim impairment assessment of the acquired IPR&D intangible asset.” · word for word

Pre-revenue biotech with significant net loss; cash runway into Q4 2027 but no approved products.

“Net loss of $93.1M; no product revenue; cash runway into Q4 2027.”

Regulatory approval risk for envudeucitinib NDA.

“NDA submission and approval subject to regulatory review.”

Clinical trial failure risk for SLE and other indications; reliance on single drug candidate envudeucitinib.

“Potentially pivotal Phase 2b clinical topline data for envudeucitinib in SLE anticipated 3Q 2026” · word for word

No approved products or revenue

“We have no product candidates approved for commercial sale and have not generated any revenue.” · word for word

Substantial losses and need for additional capital

“We will need to raise additional financing to continue our products’ development for the foreseeable future, and until we become profitable, if ever.” · word for word

Clinical trial failure risk

“we discontinued our proof-of-concept Phase 2a clinical trial of envu in patients with non-infectious uveitis in June 2024 based on the efficacy results of a data analysis prepared for a scheduled monitoring committee meeting, which efficacy results did not meet our clinical threshold for success” · word for word

Competition from established therapies

“If approved, envu would compete with several currently approved or late-stage oral clinical therapeutics in each such indication as well as other drugs used to treat such patients.” · word for word

Regulatory approval uncertainty

“The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable” · word for word

Dilution risk from large equity offering.

“17,650,000 shares offered, plus over-allotment of 2,647,500 shares.”

Preliminary financial data subject to change upon completion of audit.

“The Company has not yet completed its quarter-end or year-end financial close process ... subject to change.” · word for word

Litigation risk from contractual dispute with Climb Bio over milestone payments; potential for legal costs and delayed revenue.

“Climb Bio filed a declaratory judgment action in Delaware Superior Court asserting that its drug candidate, budoprutug, does not constitute a 'Product' as defined in the APA.” · word for word

No approved products or revenue

“We have no product candidates approved for commercial sale and have not generated any revenue.” · word for word

Need for additional capital

“Based on our current operating plan, we will need to raise additional financing to continue our products’ development for the foreseeable future.” · word for word

Clinical trial failure risk

“We discontinued our proof-of-concept Phase 2a clinical trial of envu in patients with non-infectious uveitis in June 2024 based on the efficacy results of a data analysis prepared for a scheduled monitoring committee meeting, which efficacy results did not meet our clinical threshold for success.” · word for word

Safety and tolerability risk

“As of September 30, 2025, there were four SAEs from the STRIDE OLE trial that were considered related to envu treatment by the investigator: one serious infection case (peritonsillar abscess), two malignancy cases (non-small cell lung cancer, renal cell carcinoma), and one arthritis case.” · word for word

Competitive pressure

“We face competition from entities that have made substantial investments into the rapid development of competitor treatments for immunological indications, including large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies and/or candidates under development in our current indications.” · word for word

Clinical trial failure risk for envudeucitinib and other pipeline assets.

“Phase 3 ONWARD and Phase 2b LUMUS data readouts are key milestones; failure could impair valuation.”

Cash burn rate may require future financing before profitability.

“Net loss of $110.8M in Q3 2025; cash $377.7M provides runway into 2027 but no product revenue.”